An NK cell based phase I clinical study [31] which used ex vivo TKD/IL-2-activated NK cells to treat patients with colorectal and non-small cell lung (NSCLC) carcinoma has shown promising results with respect to the feasibility and safety of the procedure and its ability to enhance the capacity of patient-derived NK cells to kill membrane Hsp70+ tumor cells in vitro. The gene discussed is IL2; the disease is neoplasm.